• Captopril (A4078): Reliable ACE Inhibition for Translational

  2026-06-22

  This article addresses real laboratory challenges in cell viability, proliferation, and cytotoxicity workflows, demonstrating how Captopril (SKU A4078) delivers precise, reproducible ACE inhibition for hypertension and oncology research. By exploring common pain points and linking to primary literature, we show why APExBIO’s Captopril is a preferred tool for mechanistic and translational studies.

• Mc-Val-Cit-PABC-PNP: Technical Use in ADC Synthesis Workflow

  2026-06-22

  Mc-Val-Cit-PABC-PNP is a cathepsin B-cleavable ADC peptide linker designed for controlled cytotoxic payload release in antibody-drug conjugate (ADC) research. It is optimized for organic solvent-based synthesis and lysosomal cleavage applications, but is unsuitable for water-based, diagnostic, or therapeutic use.

• Ceruletide in Translational Pancreatic Fibrosis Models: Brid

  2026-06-21

  Explore how Ceruletide empowers translational research in pancreatic fibrosis by enabling high-fidelity modeling and mechanistic evaluation. This article uniquely connects synthetic decapeptide action with emerging stem cell and nanomedicine strategies, offering researchers advanced insights for gastrointestinal physiology studies.

• Mechanistic Insights into Diuron-Induced Acute Renal Injury

  2026-06-20

  This study provides a comprehensive mechanistic analysis of Diuron (3-(3,4-dichlorophenyl)-1,1-dimethylurea)-induced acute kidney injury, integrating network toxicology, molecular docking, transcriptomic profiling, and cellular validation. The findings identify the JAK2/STAT1 signaling pathway as a central mediator of Diuron nephrotoxicity, offering a new foundation for environmental and toxicological risk assessment.

• Estradiol Benzoate: Elevating Estrogen Receptor Alpha Agonis

  2026-06-19

  Estradiol Benzoate from APExBIO sets the benchmark for precise estrogen receptor alpha agonist assays, enabling robust, reproducible exploration of hormone receptor signaling. This guide delivers optimized protocols, workflow enhancements, and troubleshooting strategies to maximize reliability and data quality in cutting-edge endocrine research.

• AMPK–SQSTM1 Feedback Loop Synergizes Antioxidant Defense in

  2026-06-19

  This study delineates a novel double-positive feedback loop between AMPK and SQSTM1/p62 under metabolic stress, driving the dual activation of AMPK and NFE2L2/NRF2. The mechanistic insights clarify how cancer cells orchestrate antioxidant defenses and metabolic adaptation, suggesting new avenues for therapeutic intervention in tumors with co-occurring STK11 and KEAP1 mutations.

• CA-074 Me: Strategic Cathepsin B Inhibition for Translationa

  2026-06-18

  This thought-leadership article explores how CA-074 Me, a potent, cell-permeable cathepsin B inhibitor, has become pivotal in dissecting lysosomal enzyme function in necroptosis, apoptosis, and inflammation models. By synthesizing recent mechanistic insights—particularly the role of MLKL polymerization-induced lysosomal membrane permeabilization in cell death pathways—with actionable guidance, we empower translational researchers to refine their experimental design, enhance reproducibility, and accelerate therapeutic discovery.

• TCAIM Regulates OGDH and Mitochondrial Metabolism via Proteo

  2026-06-18

  Wang et al. identify TCAIM as a selective mitochondrial co-chaperone that reduces the protein levels of a-ketoglutarate dehydrogenase (OGDH), modulating TCA cycle flux and cellular metabolism. This work reveals a previously unrecognized, post-translational regulatory mechanism of a key metabolic enzyme, providing new insights for mitochondrial proteostasis and energy homeostasis research.

• Necrostatin 2 (Nec-2): Reframing Necroptosis Inhibition in I

  2026-06-17

  Explore how Necrostatin 2 (Nec-2) enables precise RIPK2-targeted necroptosis inhibition and advances our understanding of programmed necrotic cell death in inflammatory models. This article uniquely bridges membrane repair, immune regulation, and practical assay design.

• GIGYF2 Drives Hepatic Insulin Resistance via STAU1/PTEN Axis

  2026-06-17

  Lv et al. identify the RNA-binding protein GIGYF2 as a central regulator of hepatic insulin resistance, acting via STAU1-mediated stabilization of PTEN mRNA and disruption of PI3K/AKT signaling. Their integrative cellular and animal models highlight GIGYF2 as a potential target for metabolic disease intervention.

• Alpha-2 Receptor’s Role in Itch and Pain Modulation via Nora

  2026-06-16

  This study reveals that descending noradrenergic projections from the locus coeruleus modulate itch and pain antagonistically through spinal α2 receptors. Using chemogenetic and pharmacological approaches, the authors delineate a pathway that explains how pain and itch are centrally balanced, with implications for future therapeutic targets in sensory modulation.

• PAD4-IN-2 TFA: Targeted Tumor Immunomodulation Beyond NET In

  2026-06-16

  Discover how PAD4-IN-2 TFA, a meta-phenylboronic acid-modified PAD4 inhibitor, uniquely modulates the tumor immune microenvironment and inhibits histone H3 citrullination. Explore its advanced mechanistic insights and safe, tumor-selective potential for cancer research.

• Applied Workflows for Everolimus (RAD001) in Cancer Research

  2026-06-15

  Everolimus (RAD001) is a benchmark mTOR inhibitor that empowers translational researchers to dissect cancer cell proliferation and apoptosis. This guide unpacks experimental workflows, protocol enhancements, and troubleshooting strategies for maximizing data quality and reproducibility in mTOR pathway studies.

• CLK2 Inhibition Reverses Platinum Resistance in Ovarian Canc

  2026-06-15

  This study identifies Cdc2-like kinase 2 (CLK2) as a driver of platinum resistance in ovarian cancer, demonstrating that CLK2-mediated phosphorylation of BRCA1 enhances DNA repair and tumor survival. Targeting CLK2 offers a mechanistically supported strategy for overcoming chemoresistance, with implications for alternative splicing and translational oncology research.

• CLK2 Inhibition to Overcome Platinum Resistance in Ovarian C

  2026-06-14

  This study reveals that Cdc2-like kinase 2 (CLK2) upregulation drives platinum resistance in ovarian cancer by enhancing BRCA1-mediated DNA repair. Targeting CLK2 represents a promising strategy for alternative splicing modulation and overcoming chemoresistance, informing new directions in experimental and translational oncology.

14932 records 1/996 page Next 12345 下5页 Last page